Golden
Amicus Therapeutics

Amicus Therapeutics

A biotechnology company developing therapies to cure rare diseases

Amicus Therapeutics is a publicly listed biotechnology company focused on the discovery, development, and delivery of treatments for rare metabolic diseases. Headquartered in New Jersey, the company also operates officers internationally. They include the UK, Canada, Japan, Germany, France, Italy, The Netherlands, Spain, and Australia.

Products

Medication for Fabry disease

Amicus' developments include one commercialized medication for Fabry disease, an investigational enzyme replacement therapy (AT-GAA) in late stage development for the treatment of Pompe disease, and several gene therapy pipeline and growth platform for lysosomal storage disorders, including Batten Disease, Neimann-Pick Type C, Wolman Disease, and Tay Sachs.



In August 2018, the US FDA approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare and sometime fatal condition in which accumulation of fat damages several organs. It is a long-term treatment for adult patients with specific genetic mutations, which account for an estimated 35 to 50% of diagnosed cases globally. Chemically known as migalastat, the drug has also been approved in Europe, Japan, Australia, and Canada.

Medication for Pompe disease

The company's investigational therapy, AT-GAA, for Pompe disease, an inherited Lysosomal Storage (LSD) caused by a deficiency of the enzyme acid alpha-glucosidase (GAA), completed a Phase 2 safety and pharmacokinetics study in 2013.

Gene Therapy for Batten disease

Amicus is also conducting multiple Phase 1/2 studies for their CLN6 gene therapy to treat Batten disease, a broad class of rare, fatal, inherited disorders of the nervous system known as neuronal ceroid lipofuscinoses (NCLs).

Funding

Series A

On July 25, 2002 Amicus Therapeutics completed their series A funding round with $2 million in funding from CHL Medical Partners. 

Series B

On May 13, 2004 Amicus Therapeutics completed their series B funding round with $31 million in funding from Canaan Partners (lead investor), Radius Venture Partners, New Enterprise Associates, Frazier Healthcare Partners, and CHL Medical Partners. 

Series C

On September 8, 2005 Amicus Therapeutics completed their series C funding round with $55 million in funding from Quaker BioVentures (lead investor), Radius Ventures, Prospect Venture Partners, Palo Alto Investors, New Enterprise Associates, Garden State Life Sciences Venture, Frazier Healthcare Partners, Canaan Partners, and CHL Medical Partners. 

Timeline

March 30, 2019

Series C funding round

On September 8, 2005 Amicus Therapeutics completed their series C funding round with $55 million in funding from Quaker BioVentures (lead investor), Radius Ventures, Prospect Venture Partners, Palo Alto Investors, New Enterprise Associates, Garden State Life Sciences Venture, Frazier Healthcare Partners, Canaan Partners, and CHL Medical Partners. 

March 30, 2019

Series B funding round

On May 13, 2004 Amicus Therapeutics completed their series B funding round with $31 million in funding from Canaan Partners (lead investor), Radius Venture Partners, New Enterprise Associates, Frazier Healthcare Partners, and CHL Medical Partners. 

July 25, 2002

Series A funding round

On July 25, 2002 Amicus Therapeutics completed their series A funding round with $2 million in funding from CHL Medical Partners. 

Funding rounds

1 Result
Funding round
Funding round
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn

Adriane Schilling

Employee



Allan Powe

Employee



Anne-Lise Wohlers

Employee



Bradley L. Campbell

President & COO



Christopher Holterhoff

Employee



connor ratycz

Employee



Daphne Quimi

Senior VP, Finance and Administration



David Clark

Chief People Officer



David Palling

Employee



Deyun Wang

Employee



Edward (Ed) Kawamura

Employee



Ellen S. Rosenberg

General Counsel & Corporate Secretary



Jack Kenney

Employee



Jay A. Barth

Chief Medical Officer



Jeffrey P. Castelli

Chief Portfolio Officer



Jennifer Wilson

Employee



John F. Crowley

Chairman & CEO



Kimberly Siu

Employee



Martin Warner

Employee



Nick Peist

Employee



shankar satchit

Employee



William D. Baird, III

CFO



Further reading

Title
Author
Link
Type
Date

Amicus Therapeutics receives U.S. approval for Fabry disease drug

Robin Respaut

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References